Literature DB >> 33822238

Atrial fibrillation during pregnancy: a 9-month period with limited options.

Konstantinos Iliodromitis1, Jacek Kociszewski2, Harilaos Bogossian3.   

Abstract

Pregnancy is a physiological condition with reversible hemodynamic, neurohormonal and coagulation changes to the maternal body during this 9‑month period. The occurrence of atrial fibrillation (AF) is altogether rare among pregnant women, but necessitates immediate treatment und further work-up. Despite numerous pharmacological and invasive therapeutic modalities for AF in non-pregnant patients, very few options are considered safe enough for the fetus and the mother during pregnancy. Commonly used medications such as beta blockers, calcium channel antagonists, antiarrhythmic drugs and anticoagulation therapy must be carefully individualized according to the week of gestation and possible underlying comorbidities of the mother, thus highlighting the importance of an interdisciplinary evaluation by a cardiologist and a gynecologist. The current review summarizes the existing knowledge and treatment options for AF in pregnancy and suggests a simplified algorithm for this clinical constellation.

Entities:  

Keywords:  AF; Antiarrhythmic drugs; Anticoagulation; Fetal growth; Maternal body

Year:  2021        PMID: 33822238     DOI: 10.1007/s00399-021-00751-w

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  51 in total

Review 1.  Adaptation of the maternal heart in pregnancy.

Authors:  S Hunter; S C Robson
Journal:  Br Heart J       Date:  1992-12

2.  Hemodynamics at rest and during exercise in normal pregnancy as studies by cardiac catheterization.

Authors:  R A BADER; M E BADER; D F ROSE; E BRAUNWALD
Journal:  J Clin Invest       Date:  1955-10       Impact factor: 14.808

Review 3.  Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis.

Authors:  Darae Ko; Faisal Rahman; Renate B Schnabel; Xiaoyan Yin; Emelia J Benjamin; Ingrid E Christophersen
Journal:  Nat Rev Cardiol       Date:  2016-04-07       Impact factor: 32.419

4.  Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans.

Authors:  J P Greenwood; E M Scott; J B Stoker; J J Walker; D A Mary
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

5.  Sympathetic activation during early pregnancy in humans.

Authors:  Sara S Jarvis; Shigeki Shibata; Tiffany B Bivens; Yoshiyuki Okada; Brian M Casey; Benjamin D Levine; Qi Fu
Journal:  J Physiol       Date:  2012-06-11       Impact factor: 5.182

6.  Serial study of factors influencing changes in cardiac output during human pregnancy.

Authors:  S C Robson; S Hunter; R J Boys; W Dunlop
Journal:  Am J Physiol       Date:  1989-04

7.  Temporal relationships between hormonal and hemodynamic changes in early human pregnancy.

Authors:  A B Chapman; W T Abraham; S Zamudio; C Coffin; A Merouani; D Young; A Johnson; F Osorio; C Goldberg; L G Moore; T Dahms; R W Schrier
Journal:  Kidney Int       Date:  1998-12       Impact factor: 10.612

8.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

9.  Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities).

Authors:  Liping Mou; Faye L Norby; Lin Y Chen; Wesley T O'Neal; Tené T Lewis; Laura R Loehr; Elsayed Z Soliman; Alvaro Alonso
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-07

10.  A longitudinal study of maternal cardiovascular function from preconception to the postpartum period.

Authors:  Amita A Mahendru; Thomas R Everett; Ian B Wilkinson; Christoph C Lees; Carmel M McEniery
Journal:  J Hypertens       Date:  2014-04       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.